Search results for "Practice guideline"

showing 10 items of 342 documents

S3 Guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 2

2019

Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed-type hypersensitivity. The target audience also includes other health care providers and insurance funds. Based on a systematic literature search and a formal consensus process (S3), the guidelines were developed by dermatologists in collaboration with pediatricians, occupational medicine physici…

Occupational Medicinemedicine.medical_specialtyConsensusMEDLINETarget audienceDermatologyOccupational medicineImmunocompromised Host030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePregnancyHealth caremedicineHumansHypersensitivity DelayedPediatriciansChildAdverse effectAllergic contact dermatitisbusiness.industryAllergensPatch Testsmedicine.disease3. Good healthTest (assessment)Family medicineDermatitis Allergic ContactPractice Guidelines as TopicFemaleNursing StaffbusinessContact dermatitisDermatologistsJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant …

2020

Although liver transplantation (LT) is the best treatment for patients with localized hepatocellular carcinoma (HCC), recurrence occurs in 6%-18% of patients. Several factors, particularly morphological criteria combined with dynamic parameters, known before LT modify this risk and combined in prediction models may be used to stratify patients at need of variable surveillance strategies. Additional variables though likely explain differences in recurrence rates in patients with the same pre-LT HCC status. One of these variables is possibly immunosuppression (IS). Once recurrence takes place, management is highly heterogenous. Within the International Liver Transplantation Society Consensus …

OncologyAblation Techniquesmedicine.medical_specialtyCarcinoma HepatocellularConsensusmedicine.medical_treatmentConsensus Development Conferences as TopicMEDLINE030230 surgeryLiver transplantationMedical OncologyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansIn patientGrading (tumors)Societies MedicalPostoperative CareTransplantationbusiness.industryLiver NeoplasmsConsensus conferenceImmunosuppressionChemoradiotherapy Adjuvantmedicine.diseasePrognosisUnited StatesLiver TransplantationQuality of evidenceEuropeTreatment OutcomeHepatocellular carcinomaPractice Guidelines as Topic030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct

Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph node…

2014

Abstract Aim Adjuvant chemotherapy has changed dramatically in the last decades. Anthracycline-/Taxane-based and dose-dense chemotherapy regimens improved survival in node positive breast cancer. This study tries to answer the following questions: (1)Are there differences in survival dependent on chemotherapy regimens in stratified by number of positive lymph nodes/grading (G)/hormone receptor-status (HR)/T-stage? (2)Is it possible to attribute these effects to chemotherapy by only investigating patients who received 100% guideline-conform surgery, radiotherapy and endocrine therapy? Methods This is a German multi-centre (17 participating hospitals all certified as breast cancer centres) re…

OncologyAdultBridged-Ring CompoundsCancer Researchmedicine.medical_specialtyNeoplasms Hormone-DependentAxillary lymph nodesAnthracyclineDose-dense chemotherapyReceptor ErbB-2medicine.medical_treatmentBreast NeoplasmsDisease-Free SurvivalYoung AdultBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAnthracyclinesAgedRetrospective StudiesAged 80 and overChemotherapyAnalysis of VarianceTaxanebusiness.industryRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryRadiation therapymedicine.anatomical_structureTreatment OutcomeOncologyChemotherapy AdjuvantLymphatic MetastasisPractice Guidelines as TopicFemaleTaxoidsGuideline AdherencebusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicent…

2016

Elderly breast cancer patients are affected by poorer quality of life (QoL) compared to younger patients. Because QoL has a relevant impact on guideline-adherent treatment, elderly breast cancer patients are often undertreated, especially with regard to adjuvant chemotherapy, and overall survival is decreased. Thus, understanding the impact of chemotherapy on QoL in elderly patients is crucial. This study compared QoL in patients aged 65 years and 65 to 70 years receiving adjuvant chemotherapy as a secondary outcome in the prospective randomized multicenter ADEBAR trial.Patients with lymph node-positive breast cancer were prospectively randomized for either sequential anthracycline-taxane o…

OncologyCancer ResearchDocetaxel0302 clinical medicineQuality of lifeSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsMulticenter Studies as TopicAnthracyclinesLongitudinal StudiesProspective Studies030212 general & internal medicineYoung adultProspective cohort studyAntibiotics AntineoplasticAge FactorsMiddle AgedhumanitiesOncologyDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisPractice Guidelines as TopicFemaleTaxoidsFluorouracilmedicine.drugEpirubicinAdultBridged-Ring Compoundsmedicine.medical_specialtyAdolescentCyclophosphamideBreast NeoplasmsYoung Adult03 medical and health sciencesBreast cancerInternal medicinemedicineHumansCyclophosphamideAgedEpirubicinbusiness.industryCancermedicine.diseaseClinical Trials Phase III as TopicQuality of LifePatient CompliancebusinessClinical Breast Cancer
researchProduct

Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

2017

International audience; Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combina…

OncologyCancer ResearchLymphomaDrug ResistanceLymphoma Mantle-Cell[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compound0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMedicineChemotherapy ; clinical trials ; mantle cell lymphoma ; molecular targeted therapyBortezomibCombination chemotherapyclinical trialChemotherapy; clinical trials; mantle cell lymphoma; molecular targeted therapy; Hematology; Oncology; Cancer ResearchHematologyTemsirolimusEuropeLocalOncology030220 oncology & carcinogenesisIbrutinibPractice Guidelines as TopicRituximabRituximabmedicine.drugmedicine.medical_specialtymolecular targeted therapymantle cell lymphoma03 medical and health sciencesClinical Trials Phase II as TopicInternal medicineHumansChemotherapyLenalidomideclinical trialsbusiness.industryPhase II as TopicMantle-Cellmedicine.diseaseClinical trialChemotherapy; clinical trials; mantle cell lymphoma; molecular targeted therapy; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials Phase II as Topic; Drug Resistance Neoplasm; Europe; Humans; Lymphoma Mantle-Cell; Neoplasm Recurrence Local; Practice Guidelines as Topic; RituximabNeoplasm RecurrencechemistryDrug Resistance NeoplasmNeoplasmMantle cell lymphomaNeoplasm Recurrence Localbusiness030215 immunology
researchProduct

Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced Anemia

2005

It is well recognized that anemia-induced tumor hypoxia is associated with a reduced sensitivity of tumors to radiation and some forms of chemotherapy. Thus, the correction of lower hemoglobin (Hb) concentrations with recombinant human erythropoietin (rHuEPO) can play an essential role by improving tumor oxygenation. Based on evidence from a number of trials, treatment with rHuEPO will effectively ameliorate anemia and improve quality of life. However, one of the most essential prerequisites for achieving this benefit is the use of rHuEPO in agreement with the evidence-based ASCO/ASH-guidelines recommending a target Hb concentration of 12 g/dl (7.44 mmol/l).

OncologyCancer Researchmedicine.medical_specialtyAnemiamedicine.medical_treatmentAntineoplastic AgentsComorbiditylaw.inventionHemoglobinslawNeoplasmsInternal medicinemedicineHumansPractice Patterns Physicians'ErythropoietinClinical Trials as TopicChemotherapyTumor hypoxiabusiness.industryCancerAnemiaHealth Care CostsHematologyTumor Oxygenationmedicine.diseaseRecombinant ProteinsEndocrinologyOncologyErythropoietinPractice Guidelines as TopicRecombinant DNAHemoglobinbusinessmedicine.drugOncology Research and Treatment
researchProduct

Aggressive Intrinsic Subtypes in Breast Cancer: A Predictor of Guideline Adherence in Older Patients With Breast Cancer?

2015

Treatment side effects, comorbidities, and guideline-adherent treatment (GL+) influence the oncologic outcome of older breast cancer patients (oBCP) (age ≥ 70 years). The focus of this analysis was to investigate the associations among tumor characteristics, guideline adherence, and outcome and to compare these associations between younger breast cancer patients (yBCP) (age 50-69 years) and oBCP.This is a retrospective multicenter cohort study with 17 participating certified breast cancer centers. The analysis of 10,897 patient records collected from 1992 to 2008 for GL+ and clinical outcome was performed. Tumor and patient characteristics and their associations with GL+ were compared betwe…

OncologyCancer Researchmedicine.medical_specialtyPatient characteristicsBreast NeoplasmsHER2/neuCohort StudiesBreast cancerOlder patientsInternal medicinemedicineHumansStage (cooking)AgedRetrospective StudiesGynecologybiologybusiness.industryGuideline adherenceMiddle Agedmedicine.diseaseOncologyPractice Guidelines as Topicbiology.proteinFemaleGuideline AdherencebusinessTamoxifenmedicine.drugCohort studyClinical Breast Cancer
researchProduct

Metabolic classification of human rectal adenocarcinomas: a novel guideline for clinical oncologists?

2003

Based on previous findings in SCC of the human uterine cervix and of the head and neck, metastasis- and survival-related metabolic classification was performed in human rectal adenocarcinomas. Such a characterization is suggested as basis of a novel clinical guideline for an appropriate therapy of epithelium-derived malignancies.Tissue concentrations of ATP, glucose, and lactate in viable tumor regions of 33 pretherapeutically taken cryobiopsies from 24 patients were measured at a microscopic level using the technique of imaging bioluminescence.In metastatic carcinomas, lactate levels were significantly higher (mean+/-SD: 13.4+/-3.8 vs 6.9+/-2.5 micro mol/g, P = 0.0046) and glucose levels s…

OncologyMaleCancer Researchmedicine.medical_specialtyPathologyBiopsyRectumAdenocarcinomaMedical OncologyMetastasisText miningAdenosine TriphosphateInternal medicineBiopsymedicineHumansLactic AcidSurvival analysisAgedNeoplasm StagingAged 80 and overHematologymedicine.diagnostic_testbusiness.industryRectal NeoplasmsGeneral MedicineGuidelineMiddle Agedmedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureOncologyLuminescent MeasurementsPractice Guidelines as TopicAdenocarcinomaFemalebusinessJournal of cancer research and clinical oncology
researchProduct

Molecular target therapy for bone metastasis : starting a new era with denosumab, a RANKL inhibitor

2014

Abstract: Introduction: The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting. Areas covered: Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the …

OncologyMalemedicine.medical_specialtySettore MED/06 - Oncologia MedicaClinical BiochemistryAntineoplastic AgentsBone NeoplasmsAntibodies Monoclonal HumanizedZoledronic AcidMetastasisProstate cancerBreast cancerInternal medicineDrug DiscoverymedicineAnimalsHumansMolecular Targeted TherapyBiologyPharmacologyDiphosphonatesbusiness.industrybone metastasis breast cancer denosumab prostate cancer skeletal-related events solid tumorsRANK LigandImidazolesBone metastasismedicine.diseaseSurgeryZoledronic acidDenosumabTreatment OutcomeMonoclonalPractice Guidelines as TopicHuman medicineDenosumabbusinessRANKL InhibitorEngineering sciences. Technologymedicine.drugExpert opinion on biological therapy
researchProduct

Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM

2014

Background and purpose: A substantial reduction of uncertainties in clinical brachytherapy should result in improved outcome in terms of increased local control and reduced side effects. Types of uncertainties have to be identified, grouped, and quantified. Methods: A detailed literature review was performed to identify uncertainty components and their relative importance to the combined overall uncertainty. Results: Very few components (e.g., source strength and afterloader timer) are independent of clinical disease site and location of administered dose. While the influence of medium on dose calculation can be substantial for low energy sources or non-deeply seated implants, the influence…

OncologyRadiology Nuclear Medicine and imagingNeoplasmsDosimetryPractice Guidelines as TopicBrachytherapyUncertaintyHumansHematologyDose Fractionation RadiationGuidelinesUncertaintiesTreatment planning
researchProduct